Literature DB >> 12034444

Refolding and structural characterization of the human p53 tumor suppressor protein.

Stefan Bell1, Silke Hansen, Johannes Buchner.   

Abstract

The human tumor suppressor p53 is a conformationally flexible and functionally complex protein that is only partially understood on a structural level. We expressed full-length p53 in the cytosol of Escherichia coli as inclusion bodies. To obtain active, recombinant p53, we varied renaturation conditions using DNA binding activity and oligomeric state as criteria for successful refolding. The optimized renaturation protocol allows the refolding of active, DNA binding p53 with correct quaternary structure and domain contact interfaces. The purified protein could be allosterically activated for DNA binding by addition of a C-terminally binding antibody. Analytical gelfiltration and chemical cross-linking confirmed the tetrameric quaternary structure and the spectroscopic analysis of renatured p53 by fluorescence and circular dichroism, suggested that native p53 is partially unstructured.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034444     DOI: 10.1016/s0301-4622(02)00011-x

Source DB:  PubMed          Journal:  Biophys Chem        ISSN: 0301-4622            Impact factor:   2.352


  12 in total

1.  The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis.

Authors:  Lei Jiang; Yushu Ma; Jinzhi Wang; Xinyi Tao; Dongzhi Wei
Journal:  Mol Biol Rep       Date:  2007-01-06       Impact factor: 2.316

2.  Time-Resolved Fluorescence Anisotropy Study of the Interaction Between DNA and a Peptide Truncated from the p53 Protein Core Domain.

Authors:  Chengxuan Liu; Gaiting Liang; Zhen Liu; Lily Zu
Journal:  J Fluoresc       Date:  2013-11-19       Impact factor: 2.217

3.  Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Authors:  Subbiah Elankumaran; Vrushali Chavan; Dan Qiao; Raghunath Shobana; Gopakumar Moorkanat; Moanaro Biswas; Siba K Samal
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  The DNA-binding domain mediates both nuclear and cytosolic functions of p53.

Authors:  Ariele Viacava Follis; Fabien Llambi; Li Ou; Katherine Baran; Douglas R Green; Richard W Kriwacki
Journal:  Nat Struct Mol Biol       Date:  2014-05-11       Impact factor: 15.369

5.  Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Authors:  Jacqueline L Y Chee; Suzan Saidin; David P Lane; Sai Mun Leong; Jacqueline E Noll; Paul M Neilsen; Yi Ting Phua; Hani Gabra; Tit Meng Lim
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

6.  Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice.

Authors:  S Justesen; S Buus; M H Claesson; A E Pedersen
Journal:  Immunology       Date:  2007-07-04       Impact factor: 7.397

7.  Chemical assistance in refolding of bacterial inclusion bodies.

Authors:  Mona Alibolandi; Hasan Mirzahoseini
Journal:  Biochem Res Int       Date:  2011-08-01

8.  Transduction of Recombinant M3-p53-R12 Protein Enhances Human Leukemia Cell Apoptosis.

Authors:  Tsung Chi Lu; Guan-Hao Zhao; Yao Yun Chen; Chia-Ying Chien; Chi-Hung Huang; Kwang Hui Lin; Shen Liang Chen
Journal:  J Cancer       Date:  2016-06-28       Impact factor: 4.207

9.  Semisynthetic 'designer' p53 sheds light on a phosphorylation-acetylation relay.

Authors:  Sofia Margiola; Karola Gerecht; Manuel M Müller
Journal:  Chem Sci       Date:  2021-05-19       Impact factor: 9.825

Review 10.  Refolding techniques for recovering biologically active recombinant proteins from inclusion bodies.

Authors:  Hiroshi Yamaguchi; Masaya Miyazaki
Journal:  Biomolecules       Date:  2014-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.